

Eisai Co., isai is a Human Health Care Corporation

striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.

FOR IMMEDIATE RELEASE

No. 07-35

August 10, 2007

Eisai Co., Ltd.

UK High Court Ruled NICE Guidance for Alzheimer's Disease Discriminatory

[®] (generic name: donepezil hydrochloride), for NHS patients with newly diagnosed mild Alzheimer's disease in its Guidance. In today's ruling, the Court ordered NICE to produce a draft amendment for Guidance.

In January 2007, Eisai Limited, supported by its co-promotion partner Pfizer Limited (Managing Director: John Young), formally applied for a Judicial Review of the process by which NICE published its Guidance issued in November 2006, on the following grounds:

Procedural: since NICE had repeatedly refused to disclose a fully working version of the cost effectiveness model used to evaluate the health economic value of the anti-dementia medicines, the process leading to NICE's decision breaches the principles of procedural fairness.

Irrationality: some of the assumptions made or c

<Notes to Editors>

NICE Guidance for Alzheimer's Disease

The National Institute for Health and Clinical Excellence (NICE) publishes Guidance for the standard NHS healthcare practice for treating medical conditions based on health economic evaluation of medicines, devices or procedures by the Health Technology Assessment. In producing the Guidance issued in November 2006, NICE evaluated the cost effectiveness of the anti-dementia treatments, including *Aricept*[®] which concluded that the medicines should be prescribed for NHS patients with moderate Alzheimer's disease but not for newly diagnosed mild Alzheimer's disease.

Mild Alzheimer's Disease

There are various types of scales used for diagnosis of Alzheimer's disease stage. The Mini Mental State Examination (MMSE) score used in NICE's evaluation defines the progression stage of the disease on a scale that ranges from 0-30. On the MMSE scale, scores of 30-27 are considered normal while the scores of 26 and below indicates Alzheimer's disease with the scores of 26-21 indicates mild stage, 20-10 moderate, and scores of 10 or less are in severe stage.

Judicial Review principles vs types of scales of Abuse - BC v NICE Group that the impact of